Evropska unija -
slovenščina -
EMA (European Medicines Agency)
avandamet
smithkline beecham plc - rosiglitazone, metformin hidroklorid - diabetes mellitus, tip 2 - zdravila, ki se uporabljajo pri diabetesu - avandamet je navedeno v zdravljenju diabetesa tipa 2 bolezni bolniki, zlasti s prekomerno telesno težo bolnikov:kdo se more doseči zadostne glycaemic nadzor na njihovo maksimalno dopustne odmerek peroralne metformin sam. v trojni oralna terapija z sulfonil sečnine v bolniki z nezadostno glycaemic nadzor kljub dvojno oralna terapija z njihovo maksimalno dopustne odmerek metforminom in sulfonil sečnine (glej poglavje 4.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
persantin 10 mg/2 ml raztopina za infundiranje
sanolabor, d.d. - dipiridamol - raztopina za infundiranje - dipiridamol 10 mg / 2 ml - dipiridamol
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
persantin 10 mg/2 ml raztopina za infundiranje
sanolabor, d.d. - dipiridamol - raztopina za infundiranje - dipiridamol 10 mg / 2 ml - dipiridamol
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
dalacin 100 mg vaginalne globule
pfizer luxembourg sarl - klindamicin - vaginalna globula - klindamicin 84,15 mg / 1 vag. globula - klindamicin
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
klimicin t 1% dermalna raztopina
lek d.d. - klindamicin - dermalna raztopina - klindamicin 10 mg / 1 ml - klindamicin
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
imatinib koanaa
koanaa healthcare gmbh - imatinib mesilate - leukemia, myelogenous, chronic, bcr-abl positive; precursor cell lymphoblastic leukemia-lymphoma; myelodysplastic-myeloproliferative diseases; hypereosinophilic syndrome; dermatofibrosarcoma; gastrointestinal stromal tumors - antineoplastična sredstva - imatinib koanaa is indicated for the treatment ofadult and paediatric patients with newly diagnosed philadelphia chromosome (bcr-abl) positive (ph+) chronic myeloid leukaemia (cml) for whom bone marrow transplantation is not considered as the first line of treatment. adult and paediatric patients with ph+ cml in chronic phase after failure of interferon-alpha therapy, or in accelerated phase or blast crisis. adult and paediatric patients with newly diagnosed philadelphia chromosome positive acute lymphoblastic leukaemia (ph+ all) integrated with chemotherapy. adult patients with relapsed or refractory ph+ all as monotherapy. adult patients with myelodysplastic/myeloproliferative diseases (mds/mpd) associated with platelet-derived growth factor receptor (pdgfr) gene re-arrangements. adult patients with advanced hypereosinophilic syndrome (hes) and/or chronic eosinophilic leukaemia (cel) with fip1l1-pdgfrα rearrangement. the effect of imatinib on the outcome of bone marrow transplantation has not been determined. imatinib koanaa is indicated forthe treatment of adult patients with kit (cd 117) positive unresectable and/or metastatic malignant gastrointestinal stromal tumours (gist). the adjuvant treatment of adult patients who are at significant risk of relapse following resection of kit (cd117)-positive gist. bolniki, ki imajo nizko ali zelo nizko tveganje za ponovitev, ne bi smel imeti adjuvant treatment. the treatment of adult patients with unresectable dermatofibrosarcoma protuberans (dfsp) and adult patients with recurrent and/or metastatic dfsp who are not eligible for surgery. in adult and paediatric patients, the effectiveness of imatinib is based on overall haematological and cytogenetic response rates and progression-free survival in cml, on haematological and cytogenetic response rates in ph+ all, mds/mpd, on haematological response rates in hes/cel and on objective response rates in adult patients with unresectable and/or metastatic gist and dfsp and on recurrence-free survival in adjuvant gist. the experience with imatinib in patients with mds/mpd associated with pdgfr gene re-arrangements is very limited (see section 5. razen v novo diagnozo kronične faze cml, ni kontroliranih preskušanjih, dokazujejo kliničnih koristi ali poveča preživetje pri teh bolezni.
Evropska unija -
slovenščina -
EMA (European Medicines Agency)
rapiscan
ge healthcare as - regadenoson - myokardno perfuzijsko slikanje - srčna terapija - to zdravilo je samo za diagnostično uporabo. rapiscan je selektivno koronarnih vazodilatator za uporabo kot farmakološke stres agent za radionuklid miokardni perfuzijo imaging (mpi) pri odraslih bolnikih, ne more opraviti ustrezno uresničevanje stres.
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
klindamicin 1% dermalna raztopina
dermalna raztopina - klindamicin
Slovenija -
slovenščina -
JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)
dipiridamol
obložena tableta - dipiridamol